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ABSTRACT 
In the psoriatic skin laminin integrity is altered, which could lead to insufficient laminin 
integrin interactions, leaving the α6-integrin exposed and possibly accessible for 
autoantibody production. Therefore we investigated the presence of anti-α6 integrin 
autoantibodies in the serum of patients with psoriasis vulgaris (Ps), psoriatic arthritis 
(PsA) and rheumatoid arthritis (RA) in comparison to healthy donors. The level of 
circulating anti-α6 integrin antibodies was determined by ELISA using α6 integrin 
fragments. Antibodies against at least one recombinant fragment were found in 
approximately 30% of Ps and PsA patients. In contrast, in RA patients the frequency of 
antibodies was similar to healthy controls. Our study shows the presence of anti-α6 
integrin antibodies in Ps and PsA but not in RA, which could indicate ongoing abnormal 
processes in the skin. Anti-α6 integrin autoantibodies may contribute to the formation of 
micro-wounds in the skin and to the characteristic wound healing phenotype in 
psoriasis. 
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INTRODUCTION 
 
Psoriasis is a chronic, immune-mediated disease with predominantly skin and/or 
joint manifestation affecting approximately 1.5-2% of the population worldwide. The 
disease is not homogenous in its clinical presentation, but the most frequent form of 
plaque type psoriasis vulgaris (Ps) is characterized by chronic inflammation of the skin 
resulting in scaly, raised, well-demarcated erythematous plaques. In 20% of the cases 
psoriasis is associated with arthritis or other types of musculoskeletal involvement such 
as enthesitis, spondylitis or dactylitis, causing severe pain, morning stiffness, soft-tissue 
swelling and occasionally leading to the deformation of joints 1. Psoriatic arthritis (PsA) 
has several features in common with psoriasis, but it is also considered a distinct disease 
2
. PsA has some similarities radiographically to rheumatoid arthritis (RA), and 
occasionally it may be difficult to differentiate between the two joint diseases especially 
in patients with mild cutaneous signs 3. 
The pathogenesis of psoriasis is not yet fully understood. It is considered a 
multifactorial genetic inflammatory disease, triggered by environmental factors. Recent 
studies have suggested that T helper 1, T helper 17 lymphocytes and their characteristic 
cytokines are primary modulators of inflammation in psoriasis 4,5. Data indicate that 
keratinocyte hyperproliferation triggered by skin-infiltrating T cells plays an important 
role in the formation of psoriatic lesions 6. A few reports have also demonstrated 
autoantibody production including antinuclear, anti-double-stranded DNA and anti-
thyroid microsomal antibodies 7–10.  
Integrins are known to mediate cell-cell and cell-extracellular matrix interactions 
and signaling influencing cell survival, differentiation, migration and apoptosis 11,12. 
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There are 24 different members of integrins, among them the α6β4 integrin plays an 
important role in cell to extracellular matrix connections. Together with α6β1, the α6β4 
integrin is the major laminin-binding receptor on the cell surface 13. Laminin can be 
detected around the synovial lining cells in normal and in less inflamed rheumatoid 
synovium, but in RA with severe inflammation laminin expression is diminished 14. The 
α6β4 integrin is expressed by epidermal keratinocytes and localized primarily at the 
basal surface of basal cells, where it plays a fundamental structural role in the formation 
of hemidesmosomes 15. In the healthy skin, basal keratinocytes are tightly and 
continuously anchored to the basement membrane via their integrin receptors at the 
dermal-epidermal junction (DEJ). The α6β1 integrin is strongly expressed in the normal 
synovial tissue by synovial lining cells 14. It is known that there is no basement 
membrane in the normal synovium, but the presence of laminin has been shown in the 
extracellular matrix around synovial cells. On the other hand, in RA with a severe 
inflammation, both laminin as well as the α6 integrin subunit expression is absent. The 
complete lack of the ligand may explain the downregulation of α6 integrin 16. 
The α6 integrin knockout mice died shortly after birth with severe blistering defects of 
the skin 17. Niculescu C. et al. had investigated the effect of the loss of the endothelial α6 
integrin subunit using α6fl/--K14-Cre-ERT2 mice. They found that the mutant epidermis 
resembled many histological features of inflammatory skin disorders, such as psoriasis, 
with epidermal hyperplasia, hyperkeratosis and infiltration of immune cells 18. 
Because alteration in laminin integrity is described in psoriatic uninvolved and 
involved skin 19,20, we hypothesized, that this could lead to insufficient laminin integrin 
interactions leaving the integrin exposed and accessible to immune cells, which may 
trigger the production of anti α6-integrin autoantibodies.  
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Thus, the aim of this study was to investigate the presence of circulating anti-α6 integrin 
autoantibodies in the serum of patients with Ps and PsA. 
  
 
 
MATERIALS AND METHODS 
 
PATIENTS 
We used serum samples from 62 patients with Ps, 46 patients with PsA, 52 healthy 
blood donors and, as an additional control group, 54 RA patients to investigate for the 
presence of anti-α6 integrin autoantibodies. The study was approved by the Human 
Investigation Review Board of the University of Szeged and carried out in compliance 
with the Helsinki declaration. Serum samples were collected at regular visits, regardless 
of ongoing treatments or clinical status of the patients. All psoriatic patients displayed 
skin lesions and the PsA was clinically and radiologically verified. Demographic and 
clinical data of the patients are presented in Table 1. 
 
ANTIGENIC EPITOPES WITHIN THE HUMAN α6 INTEGRIN PROTEIN  
The sequence of human α6 integrin from the Swiss Prot and TrEMBL databanks was 
analyzed with the Wisconsin Package, Version 8 software (Genetic Computer Group, 
Madison, WI) using the PeptideStructure and PlotStructure functions to select three 
fragments (abbreviated as TPAC, SVLP, SPDA) predicted to have elevated 
immunogenic properties 21. Bovine serum albumin (BSA) conjugated dimers of 
immunogenic peptide constructs were obtained from ProteoGenix. 
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DETECTION OF ANTI-α6 INTEGRIN ANTIBODY BY ELISA 
Antigenic peptide constructs were dissolved and diluted in phosphate-buffered saline 
(PBS, pH 7.4). Microplates were coated overnight with antigen solutions of 10 µg/ml 
concentration at 4 oC. After washing the wells with distilled water blocking was 
performed with PBS containing 5 % of FBS for 1.5 hours at 37 oC. Serum samples of 
patients and healthy controls were diluted 1:200 in PBS-Tween (PBST), and incubated 
in the wells for 1 hour at 37 oC followed by extensive washing with PBST. Biotinylated 
anti-human IgG antibody (1 µg/ml, Vector Laboratories) was added to each well and 
plates were incubated for 1 hour at 37 oC. After washing with PBST plates were 
incubated with ExtrAvidin™-Peroxidase (Sigma-Aldrich, USA) for 30 minutes at 37 
oC. Plates were extensively washed with PBST and 100 µl substrate solution (17 mg o-
phenylenediamine dissolved in 50 ml phosphate-citric acid buffer, pH 5.0, containing 
20 µl 30% H2O2) was added to each well. The color reaction was allowed to develop for 
5-10 min at room temperature in the dark. The reaction was stopped by the addition of 
4N H2SO4 and optical density (OD) was measured at 492 nm.  
Cut-off values were calculated by MV±2SD (MV: mean OD value of healthy control 
subjects, SD: standard deviation of the control ODs). Ten healthy samples representing 
the cut-off value of the 52 healthy controls were used of all measurements. Patients 
displaying autoantibodies against at least one antigenic epitope of α6 integrin were 
considered as positive. 
 
STATISTICS  
Statistical analysis was performed with two way chi-square test followed by Holm-
Bonferroni correction.  
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RESULTS 
 
Ps patients showed a positive reaction with a higher frequency against the 
antigenic epitopes (11.3% for TPAC and 21% for SVLP), compared to PsA patients 
(8.7% for TPAC and 17.4% for SVLP). However, autoantibodies for the SPDA 
antigenic peptide were detected more often in the PsA sera (Ps 3.2% and PsA 8.7%). 
Although the observed differences did not reach the level of statistical significance, a 
strong tendency towards a higher level of autoantibodies recognizing TPAC and SVLP 
epitopes were observed more frequently in patients with Ps and PsA, compared to 
healthy controls (3.8% for TPAC, 5.8% for SVLP, 5.8% for SPDA). In contrast, 
patients with RA displayed antibodies in similar proportion as those of the healthy 
control group (3.7% for TPAC, 5.6% for SVLP, 3.7% for SPDA). 
Next we examined the distribution of antibodies against at least one recombinant 
epitope of α6 integrin in patients with Ps and PsA, RA and healthy controls. Antibodies 
against at least one recombinant epitope of α6 integrin were found in 30.65% and 
28.26% of patients with Ps and PsA, respectively. Whereas, anti-α6 integrin antibodies 
were only present in 9.3 % of the patients with RA (Figure 1.) For the comparison of 
patients with Ps, PsA, RA and healthy controls we used the two way chi-square test. 
The test resulted in a p-value of 0.0154, indicating that differences between the different 
groups did not occur by chance. 10.5% of positive Ps and 23.1% of positive PsA 
patients presented autoantibodies to more than one antigenic peptides of α6 integrin. 
One Ps patient and one RA patient displayed autoantibodies against all of the three 
chosen antigenic peptides.  
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Positivity for anti-α6 integrin antibodies displayed an inverse significant 
correlation to the age of onset of psoriasis. Approximately 36.7% of patients who 
exhibited early appearance of disease were positive for anti-α6 integrin antibodies, 
while patients with late disease onset presented autoantibodies only in 7.7%.  
About 71% of the Ps patients received some form of systemic treatment at the 
time of blood sampling and almost all of the patients with PsA were treated with 
systemic therapy (96%). In patients who received systemic therapy, the occurrence of 
anti-α6 integrin antibodies was detected to a similar extent (31.8%) as in the non-
systemic therapy group (27.8%). 
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DISCUSSION 
The altered activation of the cellular immune system in psoriasis has been in 
focus of research for decades. In contrast, the role of the humoral immune response in 
the pathogenesis of psoriasis has only been recognized recently, and relatively few data 
are available in the literature regarding circulating autoantibodies. Recent studies have 
shown the presence of antibodies against the protease inhibitor calpastatin, anti-stratum 
corneum antibodies, anti-thyroid microsomal antibodies, antinuclear antibodies and 
anti-double-stranded DNA antibodies in Ps patients, and concluded that latent 
autoimmune disease may develop in Ps patients, without any clinical symptoms 
resulting from the formation of these antibodies 7–9,22,23. The presence of the anti-cyclic 
citrullinated peptide antibody has also been demonstrated in patients with Ps and PsA 
10,24
. However, no specific autoantibody was identified to be characteristic of all patients 
with psoriasis. It is also unclear whether the autoantibodies present in psoriasis are 
involved in the pathogenesis of psoriasis.  
Previous studies using immunostaining and confocal laser scanning microscopy 
demonstrated structural alterations of the basement membrane characterized by irregular 
γ1 subunit of laminin integration in involved and uninvolved psoriatic skin 19,20. 
Another study has reported irregular distribution of α2 laminin chain at the DEJ in 
involved psoriatic lesions 25. Further studies have demonstrated that the perturbation of 
basement membrane was one of the very earliest changes during the development of 
psoriatic lesions. This finding suggests a potential antigen localized at the DEJ playing a 
role in the initiation of the disease. In addition, it has been shown that the disruption of 
basement membrane is specific for psoriasis compared to other common inflammatory 
diseases 26. 
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We hypothesized that alteration in laminin integrity in the psoriatic skin leads to 
insufficient laminin integrin interactions, thereby leaving the integrin exposed and 
accessible to immune cells, which may trigger the production of anti α6-integrin 
autoantibodies. The autoantibodies could only indicate ongoing abnormal processes in 
the skin without taking part in the pathomechanism, but they could also contribute to the 
formation of micro-wounds in the skin, therefore participating in the induction of a 
chronic wound healing phenotype, characteristic of the psoriatic skin.  
The presence of circulating anti-α6 integrin antibodies were also shown in other 
autoimmune diseases like oral pemphigoid and bullous pemphigoid where altered 
integrin mediated interactions may play a role in blister formation 21,27.  The coexistence 
of psoriasis and bullous pemphigoid was revealed by Grattan in 1985 28. Over time, 
several studies have reported on the relationship of both diseases. A rare autoimmune 
blistering disease, anti-p200 pemphigoid, which is characterized by antibodies against 
the γ1 laminin chain, shows co-association with psoriasis in approximately 30% of 
patients. Ohata et al. reported bullous pemphigoid as the most common comorbidity in 
the population of patients with coexisting psoriasis and autoimmune blistering disease, 
followed the anti-p200 pemphigoid 29. 
Previous studies stated as the common feature in bullous pemphigoid and psoriasis to be 
the damaged basement membrane. Structural changes of BM proteins may generate 
altered antigenicity, thereby leading to formations of various anti-basement membrane 
zone antibodies. Additionally, occurrence of several nonpathogenic autoantibodies may 
follow from „epitope spreading” 30,31. 
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Kobayashi et al. showed blisters limited exclusively to the psoriatic plaques. They 
suggested that due to enzymatic degradation of the basement membrane zone antigens 
could unmask in psoriatic lesions, and become available to circulating antibodies 31,32. 
In the current study, we found positivity for anti-α6 integrin autoantibodies 
approximately 31% and 28% of patients with Ps and PsA, respectively. It is worth 
noting that all patients with PsA also had skin lesions. RA patients served as a control 
group to clarify the connection between the occurrence of these autoantibodies and joint 
involvement. Among RA patients 9.3%, while in healthy controls 15.4% displayed 
antibodies. The combined analysis of all four groups (Ps, PsA, RA, healthy) for α6 
integrin positivity using the two way chi-square test indicated that differences among 
the groups did not occur by chance. However, when the groups were compared two by 
two differences did not reach the level of statistical significance.  
In our Ps and PsA patients skin symptoms were present, in contrast, RA only 
affects the joints, indicating that that the primary antigen source of anti-α6 integrin 
antibodies is likely to be located in the skin. Although our healthy control group 
included volunteers with no manifest psoriasis, PsA or RA, we can not rule out the 
possibility that increased anti-α6 integrin antibodies could indicate susceptibility to 
develop Ps or PsA. It is known that in systemic lupus erythematous the development of 
autoantibodies may precede, even by years, the appearance of clinical manifestations 33. 
Patients undergoing systemic treatments displayed autoantibodies at the same extent as 
patients who did not receive systemic therapy in our study, indicating that therapies had 
no impact on anti-α6 integrin antibody production.  
Two forms of psoriasis can be distinguished based on the onset of the disease. 
Type 1 psoriasis shows early onset (≤40years), and has a strong genetic component 
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(association with HLA-Cw6). Type 2 psoriasis manifests after 40 years of age and 
family members are usually not affected 34,35. In patients with early onset Ps the 
positivity for anti-α6 integrin antibodies was significantly more frequent than in those of 
late onset (p=0.0435), however, in the serum of PsA patients this correlation was not 
present.  
This observation is well in line with the study of Dalmády et al. where similar 
inverse correlation between the level of anti-mutated citrullinated vimentin and the age 
of Ps onset was detected, while this correlation was not seen in the PsA group 24. 
Our study provides evidence for the presence of anti-α6 integrin antibodies in 
psoriasis. Whether the observed autoantibody production is exclusively a result of the 
pathomechanism or it excites the development of the disease still remains unclear, and 
requires further elucidation. 
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FIGURE LEGENDS: 
 
Figure 1.   Distribution of the presence of all the three investigated autoantibodies in the 
different groups.  The presence of at least one antigenic epitope of α6 integrin was 
considered as positive for anti-α6 integrin autoantibodies. Columns diagram of bar chart 
shows the number and below the percentages of positive cases are indicated. The total 
numbers of investigated serum samples are shown in brackets. 
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Table I. Basic demographic and clinical characteristics of psoriasis vulgaris and 
psoriatic arthritis patients groups. MTX: methotrexate; Biological therapy: TNF 
inhibitors (infliximab, adalimumab, etanercept, golimumab), IL 12/23 inhibitor; PUVA: 
psoralen + ultraviolet A; 311 nm NB-UVB: 311 nanometer narrow-band ultraviolet B. 
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